2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2371 Engineering a novel C3d-directed CAR-T cell Platform for applications in oncology and autoimmunity

Clara Bercher-Brayer, PharmD, Simona Caterino2, Barbara Camisa3, Alessia Ugolini4, Michela Agostini5, Zulma Irene Magnani6, Martina Spiga7, Rita El Khoury8, Lucia Sergi Sergi9, Angela Andrisani10, Matteo Doglio11, Chiara Bonini, MD12
1 Experimental Haematology Unit, Division of Immunology, Transplantation and Infectious Diseases (DITID), IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
2 Experimental Haematology Unit, Division of Immunology, Transplantation and Infectious Diseases (DITID), IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
3 Experimental Haematology Unit, Division of Immunology, Transplantation and Infectious Diseases (DITID), IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
4 Experimental Haematology Unit, Division of Immunology, Transplantation and Infectious Diseases (DITID), IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
5 Vita-Salute San Raffaele University, Milan, Italy
6 Experimental Haematology Unit, Division of Immunology, Transplantation and Infectious Diseases (DITID), IRCCS San Raffaele Scientific Institute, Milan, Italy
7 Experimental Haematology Unit, Division of Immunology, Transplantation and Infectious Diseases (DITID), IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
8 Experimental Haematology Unit, Division of Immunology, Transplantation and Infectious Diseases (DITID), IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
9 Experimental Haematology Unit, Division of Immunology, Transplantation and Infectious Diseases (DITID), IRCCS San Raffaele Scientific Institute, Milan, Italy
10 Unit of Immunogenetics, Leukemia Genomics and Immunobiology Division of Immunology, Transplantation and Infectious Diseases IRCCS San Raffaele Scientific Institute, Milano, Italy
11 Experimental Haematology Unit, Division of Immunology, Transplantation and Infectious Diseases (DITID), IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy
12 Experimental Haematology Unit, Division of Immunology, Transplantation and Infectious Diseases (DITID), IRCCS San Raffaele Scientific Institute, Milan, Italy, Vita-Salute San Raffaele University, Milan, Italy

Adoptive cell therapy with Chimeric Antigen Receptor T (CAR-T) cells has transformed the treatment of several hematologic malignancies, and shown promise in the treatment of autoimmune diseases. Still, the efficacy of cellular therapy in solid tumors and autoimmune diseases remains limited by antigen heterogeneity and immune escape. In clinical practice, monoclonal antibodies (mAbs) are widely used and have been shown to effectively activate the complement cascade, resulting in stable, covalent C3d deposition on tumor cells. In autoimmune diseases, such as systemic lupus erythematosus, this same complement molecule C3d is known to deposit in the inflamed tissues and kidneys. 

Here, we propose a “universal” second-generation anti-C3d CAR platform that exploits the C3d deposition in both malignant and autoimmune diseases. 

In the tumor context, the anti-C3d CAR-T cells are combined with clinically approved mAbs to bypass antigen heterogeneity by redirecting T-cell specificity toward mAb-localized C3d deposition. In autoimmune models, anti-C3d CAR is used to redirect regulatory T cells (Tregs) to the inflamed tissues, where they can exert their immunomodulatory function and restore homeostasis of the immune system.

As proof of concept, we validated in vitro our anti-C3d CAR-T cells using a lymphoma model. Specifically, we treated Raji cell line with Rituximab and human serum to induce complement deposition and then evaluated Raji cell killing by the addition of anti-C3d CAR-T cells. Using flow cytometry-based cell counting and the Incucyte® Live-Cell Analysis System, we observed a specific tumor killing capacity of anti-C3d CAR-T cells compared to their untransduced counterpart. 

Next, by exploiting the mouse/human cross-reactivity of our CAR, we validated the efficacy of the anti-C3d CAR-T cells in vivo in a complement-competent mouse strain (BRGSF) using the same Raji lymphoma model (5x105 cells per mouse IV). Upon combination of rituximab and anti-C3d CAR-T cells, we observed a significant reduction of circulating tumor cells measured both by flow cytometry and bioluminescence analysis compared to mice treated with rituximab-only. Consistent with the potent tumor-killing capacity of CAR-T cells, we observed a significant reduction of the tumor burden in the bone marrow by flow cytometry at the endpoint of the experiment. 

Following this first validation, we applied the same combinatorial strategy in vitro using solid tumor cell lines. Importantly, we observed significant killing of HER2-expressing BxPC-3 pancreatic and SW480 colorectal cancer cell lines upon treatment with trastuzumab and anti-C3d CAR-T cells.

For autoimmune applications, the CAR construct was expressed in CD4+CD25+ T cells alongside a FOXP3 stabilizing transgene. In vitro, anti-C3d CAR-Tregs demonstrated target-specific activation and proliferation upon binding deposited C3d. Moreover, we demonstrated the suppressive capacity of the anti-C3d-CAR-Tregs upon antigen-specific stimulation. Indeed, CAR-Tregs showed a significant suppression of the proliferative capacity of activated T cells and a significant suppression of B cell activation (CD80/86) evaluated by flow cytometry. In vivo, we demonstrated the feasibility of humanizing the BRGSF complement-competent mice with CD34+ cord blood-derived stem cells and induced a lupus-like inflammation using pristane. This model will be the basis of the in vivo testing of our anti-C3d-CAR-Tregs.

To conclude, this project is the first validation of a new anti-C3d CAR, shifting from single antigen-restricted CAR-T cells to a “universal” complement-based targeting strategy. In oncology, we propose an anti-C3d CAR-T platform that exploits this mechanism to bypass antigen heterogeneity by redirecting T-cell specificity toward mAb-induced C3d deposition. In autoimmune settings, we leverage tissue-localized C3d deposition to target anti-C3d CAR-Tregs directly to inflamed lesions across multiple diseases, restoring local immune regulation.

Clara Bercher-Brayer, PharmD: No relevant conflicts of interest to declare.